US Patent Issued to Fortvita Biologics (Singapore) on Nov. 3 for "Interleukin-2 mutant and fusion protein thereof" (Chinese Inventors)

ALEXANDRIA, Va., Nov. 3 -- United States Patent no. 12,779,021, issued on Nov. 3, was assigned to Fortvita Biologics (Singapore) Pte. Ltd. (Singapore).

"Interleukin-2 mutant and fusion protein thereof" was invented by Kaijie He (Suzhou, China), Fenggen Fu (Suzhou, China), Weiwei Wu (Suzhou, China), Shuaixiang Zhou (Suzhou, China) and Jian Guan (Suzhou, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are a new interleukin-2 (IL-2) mutant protein and the use thereof. Compared with wild-type IL-2, the IL-2 mutant protein has improved properties, such as an improved IL-2 receptor binding property and improved druggability. Also provided are a fusion protein, dimer and immunoconjugate comprising th...